Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis. | MicrobiomeTrials← Back to trialsNCT06253117
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-06-27Est. Completion: 2028-09-01
Enrollment target: 60 participants Locations- University of Alabama at Birmingham, Birmingham, Alabama, United States
- University of Iowa Health Care, Iowa City, Iowa, United States
- Mayo Clinic, Rochester, Minnesota, United States
ContactSanthi Swaroop Vege, M.D.
Other microbiome trials you might be interested in
Pancreatitis, ChronicPancreatitis, AcuteDiabetes Mellitus
The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic …
Rochester, United StatesEst. completion May 31, 2027
Hypertriglyceridemic Acute PancreatitisAcute Pancreatitis, Hypertriglyceridemia-inducedHyperlipidemia
Background: Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) has become the second most common cause of acute…
Xiamen, China
Est. completion Jan 18, 2028